Comprehensive genomic analysis of early and late-onset hepatocellular carcinoma  

作　　者：Jialin Yang Chao Chen Song Wang Yaru Zhang Jiaohui Pang Yajun Wang Qiuxiang Ou Hao Jiang Juying Liu 

机构地区：[1]Department of Radiation Oncology,Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China,Chengdu,Sichuan 610041,China [2]Jinling Hospital,Department of Oncology,Nanjing Medical University,Nanjing,Jiangsu 210002,China [3]Geneseeq Research Institute,Nanjing Geneseeq Technology Inc.,Nanjing,Jiangsu 210000,China [4]Department of Oncology,Haian Hospital of Traditional Chinese Medicine,Haian,Jiangsu 226600,China [5]Interventional Therapy Department,Jiangsu Cancer Hospital&Jiangsu Institute of Cancer Research&The Affiliated Cancer Hospital of Nanjing Medical University,Nanjing,Jiangsu 210009,China

出　　处：《Genes & Diseases》2024年第4期77-81,共5页基因与疾病（英文）

基　　金：approved by the Medical Ethics Committee of Nanjing Geneseeq Medical Laboratory(NSJB-MEC-2023-02).

摘　　要：Hepatocellular carcinoma(HCC)is the major histologic type of primary liver cancer,accounting for approximately 75%of liver cancer cases.'Despite many advancements in its treatment,the prognosis and drug response of HCC patients are dismal.Therefore,there is an unmet clinical need to explore genomic aberrations underlying early-and lateonset HcC,which might facilitate drug discovery and provide personalized biomarker-driven treatment options for these patients.

关 键 词：patients PROGNOSIS CANCER 

分 类 号：R735.7[医药卫生—肿瘤]